3-Furanpropanamine | 684221-27-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-Furanpropanamine
• 英文别名: 3-(furan-3-yl)propan-1-amine
• CAS: 684221-27-0
• 化学式: C₇H₁₁NO
• 分子量: 125.17
• InChiKey: VXERVXYMGPPIAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  39.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-(furan-3-yl)acrylonitrile 、 氢气 在 镍 乙醇 、 甲醇 、 二氯甲烷 、 氨 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以afforded 3-Furan-3-yl-propylamine (0.070 g, 23.4%) as pale yellow liquid的产率得到3-Furanpropanamine
  参考文献：
  名称：

  METHODS OF MODULATING CFTR ACTIVITY

  摘要：

  本发明涵盖了调节需要的受体内CFTR活性的方法，包括给予公式（I）化合物的有效量。本发明还涵盖了治疗与CFTR活性相关的病症或与蛋白质稳态失调相关的病症的方法，包括给予受体公式（I）化合物的有效量。

  公开号：

  US20160151335A1

文献信息

• Pyrimidine derivatives as IL-8 receptor antagonists
  申请人：——

  公开号：US20040087601A1

  公开（公告）日：2004-05-06

  Compounds containing the pyrimidine nucleus and their use to treat diseases and conditions related to inappropriate Interleukin-8 receptor activity are disclosed. The compounds are of the formula I 1 In these compounds, Q is preferably unsubstituted and substituted heterocyclyl; U is usually hydrogen or fluorine; and V is preferably hydrogen, halogen, alkyl, —O—alkyl or —S-alkyl. A representative example is: 2

  含有嘧啶核的化合物及其用于治疗与不适当的白细胞介素-8受体活性相关的疾病和症状的用途已被披露。这些化合物的结构式为I 1 在这些化合物中，Q最好是未取代或取代的杂环烷基；U通常是氢或氟；V最好是氢、卤素、烷基、—O—烷基或—S-烷基。一个代表性的例子是： 2
• [EN] METHODS OF MODULATING CFTR ACTIVITY<br/>[FR] PROCÉDÉS DE MODULATION DE L'ACTIVITÉ DE CFTR
  申请人：PROTEOSTASIS THERAPEUTICS INC

  公开号：WO2014210159A1

  公开（公告）日：2014-12-31

  The invention encompasses methods of modulating CFTR activity in a subject in need thereof comprising administering an effective amount of a compound of Formula (I). The invention also encompasses methods of treating a condition associated with CFTR activity or condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a compound of Formula (I).

  这项发明涵盖了在需要的受试者中调节CFTR活性的方法，包括向受试者施用化合物Formula (I)的有效量。该发明还涵盖了治疗与CFTR活性相关的疾病或与蛋白质稳态功能障碍相关的疾病的方法，包括向受试者施用化合物Formula (I)的有效量。
• [EN] IMIDAZOLYL PYRIMIDINE DERIVATIVES USEFUL AS IL-8 RECEPTOR MODULATORS<br/>[FR] DERIVES DE D'IMIDAZOLYL PYRIMIDINE UTILISES COMME MODULATEURS DU RECEPTEUR DE IL-8
  申请人：PHARMACOPEIA DRUG DISCOVERY

  公开号：WO2004063192A1

  公开（公告）日：2004-07-29

  The invention relates to compounds of the formula I, wherein R1, R2, R3 and R4 are each independently selected from H, (1-4C)alkyl, (1-4C)alkoxy, trifluoromethyl, trifluoromethoxy, halogen, amino, sulfonamide, cyano, OH and nitro; R5 is H or (1-6C)alkyl; R6 is H, (1-6C)alkyl or (1-6C)alkoxy; R7 is H or (1-6C)alkyl; R8 is (1-6C)alkyl, optionally substituted with (1-6C)alkoxy; R9 is -(CH2)nR10, wherein n is 1, 2 or 3 and R10 is selected from (1-4C)alkoxy, (1-4C)alkylthio, trifluoromethyl, (3-8C)cycloalkyl, phenyl optionally substituted with (1-4C)alkoxy, -NR11R12 and -O(CH2)2NR11R12, wherein one of R11 and R12 is (1-4C)alkoxy, the other being H or (1-4C)alkyl, or R9 is -CH2(2-7C)heterocycloalkyl, provided that when at least one heteroatom in the heterocycloalkyl moiety is nitrogen, the distance between this nitrogen and the nitrogen in 'NHR9' is at least three carbon atoms, or R9 is -(CH2)3(2-7C)heterocycloalkyl or -(CH2)2CHR13R14, wherein R13 and R14 together with the carbon atom to which they are attached, are (2-7C)heterocycloalkyl; and X is O, S or NH; or a pharmaceutically acceptable salt thereof. The compounds of the invention are Il-8 receptor modulators, in particular inhibitors thereof, and can be used for treating or preventing Il-8 receptor mediated disorders, such as atherosclerosis, inflammation, rheumatoid arthritis and related disorders.

  该发明涉及公式I的化合物，其中R1、R2、R3和R4分别独立地选择自H、(1-4C)烷基、(1-4C)烷氧基、三氟甲基、三氟甲氧基、卤素、氨基、磺酰胺基、氰基、羟基和硝基；R5为H或(1-6C)烷基；R6为H、(1-6C)烷基或(1-6C)烷氧基；R7为H或(1-6C)烷基；R8为(1-6C)烷基，可选地取代为(1-6C)烷氧基；R9为-(CH2)nR10，其中n为1、2或3，R10选自(1-4C)烷氧基、(1-4C)烷基硫醚、三氟甲基、(3-8C)环烷基、苯基，可选地取代为(1-4C)烷氧基，-NR11R12和-O(CH2)2NR11R12，其中R11和R12中的一个为(1-4C)烷氧基，另一个为H或(1-4C)烷基，或R9为-CH2(2-7C)杂环烷基，但至少一个杂原子在杂环烷基基团中是氮时，该氮与“NHR9”中的氮之间的距离至少为三个碳原子，或R9为-(CH2)3(2-7C)杂环烷基或-(CH2)2CHR13R14，其中R13和R14与它们连接的碳原子一起，是(2-7C)杂环烷基；X为O、S或NH；或其药学上可接受的盐。该发明的化合物是Il-8受体调节剂，特别是其抑制剂，并可用于治疗或预防Il-8受体介导的疾病，如动脉粥样硬化、炎症、类风湿关节炎及相关疾病。
• TARGETING AN HIV-1 NEF-HOST CELL KINASE COMPLEX
  申请人：Emert-Sedlak Lori

  公开号：US20110190241A1

  公开（公告）日：2011-08-04

  Drug candidates for inhibition of HIV-I replication can target Src family kinases (SFK), such as Hck, that interact with Nef protein of the virus. Compounds characterized by such inhibitory activity were identified via an assay for kinase activity of an SFK in a Nef:SFK complex. Illustrative of inhibitors identified using the kinase assay are various 2,3-diaminoquinaxolines and furo[2,3-d]pyrimidines. The inventive inhibitors were found to arrest HIV-I viral replication in vitro.

  用于抑制HIV-I复制的药物候选物可以针对Src家族激酶（SFK），如与病毒的Nef蛋白相互作用的Hck进行靶向。通过对Nef:SFK复合物中SFK的激酶活性进行测定，鉴定了具有这种抑制活性的化合物。使用激酶测定鉴定的抑制剂的例子包括各种2,3-二氨基喹啉和呋喃[2,3-d]嘧啶。这些创新的抑制剂被发现可以在体外阻止HIV-I病毒的复制。
• 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF
  申请人：Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd

  公开号：EP3838900A1

  公开（公告）日：2021-06-23

  A 3-aryloxy-3-aryl-propylamine compound or a pharmaceutically acceptable salt of same, or a prodrug of same, and uses thereof. The compound has the structure of formula I. The compound, the pharmaceutically acceptable salt of same, or the prodrug of same provides an inhibitory effect with respect to a transient receptor potential (TRP) channel protein, and provides great therapeutic effects with respect to diseases related to the transient receptor potential channel protein.

  一种 3-芳氧基-3-芳基-丙胺化合物或其药学上可接受的盐或其原药及其用途。该化合物具有式 I 的结构。该化合物、其药学上可接受的盐或其原药对瞬时受体电位（TRP）通道蛋白有抑制作用，对与瞬时受体电位通道蛋白有关的疾病有很好的治疗效果。